The startup develops machine learning and artificial intelligence algorithms for drug repurposing and food supplement optimization, providing computational services that enhance drug design and development processes. By improving the efficiency of drug discovery and delivery, the company supports the pharmaceutical industry in bringing effective treatments to market more rapidly.
Funding
$570K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The pharmaceutical and nutraceutical industries face challenges in efficiently identifying promising drug candidates and optimizing formulations due to the complexity of biological systems and the vast chemical space. Traditional drug discovery and development processes are often time-consuming, costly, and have a high failure rate.
Solution
Cloudpharm provides computational R&D services, employing machine learning and AI algorithms to accelerate drug repurposing, drug design, and the development of next-generation food supplements. Their services leverage in silico methodologies to predict drug efficacy, toxicity, and interactions with the gut microbiome, as well as to optimize formulations for nutraceuticals and medical devices. By integrating 1D (genomic, transcriptomic, proteomic, metabolomic) and 3D (computational chemistry, molecular design) data, Cloudpharm aims to deliver integrated solutions that enhance the efficiency and effectiveness of pharmaceutical and health product development. The company's approach facilitates the identification of bioactive compounds, supports clinical interventions, and enables the design of novel dietary supplements with improved efficacy and tolerance.
Target Audience
Cloudpharm serves pharmaceutical companies, nutraceutical manufacturers, and research institutions seeking to leverage computational methods for drug discovery, drug repurposing, and the development of innovative health products.
Features
- AI-driven hit identification and hit-to-lead optimization for drug discovery
- Predictive modeling of toxicity and ecotoxicity for drug candidates
- Analysis of drug interactions with the gut microbiome
- Formulation development and product design for nutraceuticals and medical devices
- Computational tools for designing nutritional supplements
- Integration of 1D and 3D data for comprehensive analysis
- CloudScreen platform for drug repositioning, integrating genomic, transcriptomic, proteomic, metabolomic, and text data with computational chemistry and molecular design
- Development of companion biomarkers related to the efficacy and tolerability of new supplements